SiteOne Therapeutics Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
22
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1B
SiteOne Therapeutics General Information
Description
Developer of novel pain therapeutics designed to offer treatment for acute and chronic pain. The company's drugs provide treatment for neuropathic pain through novel pain therapeutics without the limitations of existing drugs, such as opioids, enabling healthcare professionals to deliver an optimal treatment to their patients and improve efficiency.
Contact Information
Website
www.siteonetherapeutics.comCorporate Office
- 280 Utah Avenue
- Suite 250
- South San Francisco, CA 94080
- United States
Corporate Office
- 280 Utah Avenue
- Suite 250
- South San Francisco, CA 94080
- United States
SiteOne Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Merger/Acquisition | 28-Jul-2025 | $1B | Completed | Clinical Trials - Phase 1 | ||
| 15. Later Stage VC (Series C) | 18-Dec-2024 | Completed | Clinical Trials - Phase 1 | |||
| 14. Later Stage VC | 01-Jan-2024 | Completed | Clinical Trials - Phase 1 | |||
| 13. Grant | 19-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 12. Grant | 01-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 11. Grant | 11-May-2021 | Completed | Clinical Trials - Phase 1 | |||
| 10. Grant | 10-Oct-2019 | Completed | Clinical Trials - Phase 1 | |||
| 9. Grant | 01-May-2019 | Completed | Clinical Trials - Phase 1 | |||
| 8. Grant | 01-Jan-2018 | $1.49M | $17.7M | Completed | Clinical Trials - Phase 1 | |
| 7. Later Stage VC (Series B) | 08-Jan-2017 | $15M | $17.7M | Completed | Clinical Trials - Phase 1 |
SiteOne Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 1,315,638 | $0.001000 | $0.09 | $1.15 | $1.15 | 1x | $1.15 | 15.37% |
SiteOne Therapeutics Comparisons
Industry
Financing
Details
SiteOne Therapeutics Competitors (16)
One of SiteOne Therapeutics’s 16 competitors is Centrexion Therapeutics, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrexion Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Frenelle Pharma | Venture Capital-Backed | Plymouth, MN | ||||
| Cerecin | Venture Capital-Backed | Broomfield, CO | ||||
| Curemark | Venture Capital-Backed | New York, NY | ||||
| Neuropn Therapeutics | Corporation | Alpharetta, GA |
SiteOne Therapeutics Patents
SiteOne Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025376454-A1 | Substituted cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain | Pending | 17-May-2024 | ||
| WO-2025240895-A1 | Substituted cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain | Pending | 17-May-2024 | ||
| AU-2025211735-A1 | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain | Pending | 24-Jan-2024 | ||
| WO-2025160286-A1 | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain | Pending | 24-Jan-2024 | ||
| EP-4514789-A1 | Pending | 25-Apr-2022 | C07D401/04 |
SiteOne Therapeutics Signals
SiteOne Therapeutics Former Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 2M Collective | Family Office | Minority | ||
| Amgen | Corporation | Minority | ||
| BSQUARED Capital | Family Office | Minority | ||
| Biobrit | Venture Capital | Minority | ||
| Mission Bay Capital | Venture Capital | Minority |
SiteOne Therapeutics FAQs
-
When was SiteOne Therapeutics founded?
SiteOne Therapeutics was founded in 2010.
-
Where is SiteOne Therapeutics headquartered?
SiteOne Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of SiteOne Therapeutics?
SiteOne Therapeutics has 22 total employees.
-
What industry is SiteOne Therapeutics in?
SiteOne Therapeutics’s primary industry is Drug Discovery.
-
Is SiteOne Therapeutics a private or public company?
SiteOne Therapeutics is a Private company.
-
What is the current valuation of SiteOne Therapeutics?
The current valuation of SiteOne Therapeutics is .
-
What is SiteOne Therapeutics’s current revenue?
The current revenue for SiteOne Therapeutics is .
-
How much funding has SiteOne Therapeutics raised over time?
SiteOne Therapeutics has raised $118M.
-
Who are SiteOne Therapeutics’s investors?
2M Collective, Amgen, BSQUARED Capital, Biobrit, and Mission Bay Capital are 5 of 20 investors who have invested in SiteOne Therapeutics.
-
Who are SiteOne Therapeutics’s competitors?
Centrexion Therapeutics, Frenelle Pharma, Cerecin, Curemark, and Neuropn Therapeutics are some of the 16 competitors of SiteOne Therapeutics.
-
When was SiteOne Therapeutics acquired?
SiteOne Therapeutics was acquired on 28-Jul-2025.
-
Who acquired SiteOne Therapeutics?
SiteOne Therapeutics was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process